CONMED Corp
For the period ended Mar 31, 2024. Filed Apr 25, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed Apr 25, 2024
CNMD$51.50-2.5%Stored close · as of Nov 6, 2026
Contents
– Consolidated Condensed Statements of Comprehensive Income for the three months ended March 31, 2024 and 2023
CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME
| Three Months Ended | ||
|---|---|---|
| March 31, | ||
| 2024 | 2023 | |
| Net sales | $312,273 | $295,468 |
| Cost of sales | 140,308 | 140,147 |
| Gross profit | 171,965 | 155,321 |
| Selling and administrative expense | 123,358 | 130,083 |
| Research and development expense | 13,594 | 12,539 |
| Operating expenses | 136,952 | 142,622 |
| Income from operations | 35,013 | 12,699 |
| Interest expense | 9,594 | 10,255 |
| Income before income taxes | 25,419 | 2,444 |
| Provision for income taxes | 5,710 | 625 |
| Net income | $19,709 | $1,819 |
| Comprehensive income | $20,078 | $4,695 |
| Per share data: | ||
| Net income | ||
| Basic | $0.64 | $0.06 |
| Diluted | 0.63 | 0.06 |
| Weighted average common shares | ||
| Basic | 30,780 | 30,511 |
| Diluted | 31,272 | 31,204 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.